Tenaya Therapeutics (TNYA) Income from Continuing Operations (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Income from Continuing Operations of 19272000.0 for Q1 2026, up 28.26% year-over-year from 15025627.12 in Q1 2025, and up 4.48% quarter-over-quarter from 20175000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 19272000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 28.26% year-over-year to 19272000.0; the TTM figure through Mar 2026 stood at 83005000.0 (up 21.52% YoY), while the FY2025 annual figure was 90597000.0, up 18.48% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19272000.0, up from 20175000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 19272000.0 in Q1 2026, with the low at 33516000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 29143000.0 (2023), against an average of 27573352.94.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations slumped 137.1% in 2022, then rose 28.26% in 2026.
- Tenaya Therapeutics' Income from Continuing Operations stood at 33516000.0 in 2022, then rose by 10.68% to 29935000.0 in 2023, then climbed by 20.37% to 23836000.0 in 2024, then advanced by 15.36% to 20175000.0 in 2025, then climbed by 4.48% to 19272000.0 in 2026.
- Business Quant data shows TNYA's Income from Continuing Operations at 19272000.0 in Q1 2026, 20175000.0 in Q4 2025, and 20275000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | -43.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.39 Mn |
| Mar 31, 2026 | -19.27 Mn |
| Dec 31, 2025 | -20.18 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -23.28 Mn |
| Mar 31, 2025 | -26.86 Mn |
| Dec 31, 2024 | -23.84 Mn |
| Sep 30, 2024 | -25.63 Mn |
| Jun 30, 2024 | -29.43 Mn |
| Mar 31, 2024 | -32.23 Mn |
| Dec 31, 2023 | -29.94 Mn |
| Sep 30, 2023 | -29.14 Mn |
| Jun 30, 2023 | -33.27 Mn |
| Mar 31, 2023 | -31.74 Mn |
| Dec 31, 2022 | -33.52 Mn |
| Sep 30, 2022 | -30.70 Mn |
| Jun 30, 2022 | -28.40 Mn |
| Mar 31, 2022 | -31.06 Mn |
| Dec 31, 2021 | -26.15 Mn |
| Sep 30, 2021 | -18.26 Mn |